An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis.

Cancer Discov

Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Published: January 2021

Chromosome copy-number variations are a hallmark of cancer. Among them, the prevalent chromosome 17p deletions are associated with poor prognosis and can promote tumorigenesis more than loss. Here, we use multiple functional genetic strategies and identify a new 17p tumor suppressor gene (TSG), plant homeodomain finger protein 23 (). Its deficiency impairs B-cell differentiation and promotes immature B-lymphoblastic malignancy. Mechanistically, we demonstrate that PHF23, an H3K4me3 reader, directly binds the SIN3-HDAC complex through its -terminus and represses its deacetylation activity on H3K27ac. Thus, the PHF23-SIN3-HDAC (PSH) complex coordinates these two major active histone markers for the activation of downstream TSGs and differentiation-related genes. Furthermore, dysregulation of the PSH complex is essential for the development and maintenance of -deficient and 17p-deleted tumors. Hence, our study reveals a novel epigenetic regulatory mechanism that contributes to the pathology of 17p-deleted cancers and suggests a susceptibility in this disease. SIGNIFICANCE: We identify , encoding an H3K4me3 reader, as a new TSG on chromosome 17p, which is frequently deleted in human cancers. Mechanistically, PHF23 forms a previously unreported histone-modifying complex, the PSH complex, which regulates gene activation through a synergistic link between H3K4me3 and H3K27ac..

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591992PMC
http://dx.doi.org/10.1158/2159-8290.CD-20-0336DOI Listing

Publication Analysis

Top Keywords

chromosome 17p
12
psh complex
12
h3k4me3 reader
8
complex
5
epigenetic mechanism
4
mechanism underlying
4
chromosome
4
underlying chromosome
4
17p
4
17p deletion-driven
4

Similar Publications

Background: Patients with multiple myeloma without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous stem-cell transplantation (autoHCT) are limited.

Objective: To evaluate survival outcomes for patients with SRMM receiving autoHCT, and to elucidate factors that impact these outcomes.

Study Design: Single-center retrospective analysis that included consecutive MM patients who received upfront autoHCT between 2013-2021, had available cytogenetic information and had no high-risk chromosomal abnormalities on fluorescence in situ hybridization (FISH), defined as t(4;14), t(14;16), del(17p) or 1q21 gain or amplification.

View Article and Find Full Text PDF

Upper gastrointestinal stenosis, which can be congenital or acquired, can lead to dysphagia. The association between trisomy 17p syndrome, a rare chromosomal abnormality, and upper gastrointestinal stenosis is unclear. A 20-year-old man diagnosed with trisomy 17p syndrome was referred to our department due to recurrent vomiting.

View Article and Find Full Text PDF

Risk-stratification in frontline CLL therapy: standard of care.

Hematology Am Soc Hematol Educ Program

December 2024

Comprehensive Cancer Center Ulm and Division of CLL-Internal Medicine III, Ulm University, Germany.

The treatment of chronic lymphocytic leukemia (CLL) has been transformed over the past decade based on a better understanding of disease biology, especially regarding molecular genetic drivers and relevant signaling pathways. Agents focusing on B-cell receptor (in particular Bruton tyrosine kinase [BTK]) and apoptosis (BCL2) targets have replaced chemoimmunotherapy (CIT) as the treatment standard. BTK and BCL2 inhibitor-based therapy has consistently shown prolonged progression-free survival and in some instances even increased overall survival against CIT in frontline phase 3 trials.

View Article and Find Full Text PDF

[Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].

Zhonghua Xue Ye Xue Za Zhi

October 2024

Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Myeloma Research Center of Beijing, Beijing 100020, China.

To investigate the prognosis of newly diagnosed multiple myeloma (MM) patients with t (14;16) abnormality. Clinical data from 564 patients diagnosed with initial MM from January 2018 to November 2020 at Beijing Chaoyang Hospital affiliated with Capital Medical University and the First Affiliated Hospital of Sun Yat-sen University were collected and retrospectively analyzed. The prognoses of patients with t (14;16) were analyzed and compared with the prognoses of patients with normal FISH, and those with t (4;14) and del (17p) .

View Article and Find Full Text PDF

Diagnostic challenges in complicated case of glioblastoma.

Pathol Oncol Res

November 2024

Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine of Charles University in Prague, Prague, Czechia.

Article Synopsis
  • Glioblastoma is the most common and aggressive primary brain tumor, making diagnosis difficult due to its genetic variability and poor prognosis.
  • A complex case study utilized multiple cytogenomic methods to identify key genetic markers, revealing classical glioblastoma characteristics and distinct pathological clones.
  • The study suggests an integrated approach for diagnosis, focusing on detecting genetic alterations to potentially improve patient outcomes in terms of diagnosis, prognosis, and treatment predictions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!